Probiotic Vesicles for Anti-inflammatory and Antibacterial Applications
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective substances to prevent, treat, or ameliorate inflammatory and bacterial infections, as well as to improve intestinal health, which current technologies have not adequately addressed using novel microorganisms and their derived vesicles.
Innovation Solution
The use of specific strains such as Blautia massiliensis, Blautia obeum, Blautia wexlerae, Leuconostoc lactis, and Ruminococcus bromii, along with their vesicles, lysates, and culture solutions, which exhibit anti-inflammatory and antibacterial activities, are proposed for pharmaceutical, health functional food, and cosmetic compositions to address these issues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for inflammatory and bacterial infections, then immediate therapeutic effect is achieved, but development of resistance and side effects occur
Solution Approach 1:
The patent uses vesicles derived from probiotic bacteria as intermediary carriers to deliver anti-inflammatory and antibacterial substances. These vesicles act as mediators between the probiotic bacteria and host cells, transferring beneficial substances while avoiding direct harmful interactions. The vesicles protect against bacterial resistance by delivering therapeutic agents through a natural, non-invasive mechanism that does not select for resistant strains.
Solution Approach 2:
The probiotic bacteria themselves produce and release the therapeutic vesicles, utilizing their own metabolic and cellular mechanisms to generate the treatment. The bacteria's natural vesicle production systems are harnessed to create therapeutic agents, allowing the treatment to be self-generated by the administered microorganisms rather than requiring external synthesis or processing.
2Object-affected harmful factors
If antibiotics are used to treat bacterial infections, then bacterial growth is inhibited, but disruption of intestinal microbiota balance occurs
Solution Approach 1:
The patent employs specific probiotic bacterial strains with targeted antibacterial activity against pathogenic bacteria while maintaining selectivity that spares beneficial intestinal microbiota. The vesicles and their contents are designed to act locally on specific bacterial targets rather than broadly affecting all bacteria, preserving the overall microbiota balance while treating the infection.
Solution Approach 2:
The patent introduces beneficial probiotic bacteria that produce antibacterial substances to counteract harmful pathogenic bacteria. The same antibacterial mechanism that could potentially harm beneficial bacteria is instead harnessed to eliminate pathogens, converting a potentially harmful effect into a therapeutic benefit. The probiotics establish a beneficial microbial presence that restores balance after infection.
3Adaptability or versatility
If novel microorganisms are introduced to improve intestinal health, then therapeutic potential is increased, but safety and efficacy validation requirements increase
Solution Approach 1:
The patent uses vesicles that replicate and transfer key functional components and molecules from the probiotic bacteria to host cells. Rather than requiring the entire living organism to be present and active, the vesicles carry copies of essential therapeutic molecules (proteins, lipids, nucleic acids) that reproduce the beneficial effects in a more controllable and characterizable format, reducing validation complexity while maintaining therapeutic potential.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These strains and their derived products demonstrate significant anti-inflammatory and antibacterial effects, including reducing nitric oxide production, inhibiting inflammatory cytokines, and inhibiting bacterial growth, thereby providing effective prevention, treatment, or amelioration of inflammatory diseases and bacterial infections, and improving intestinal health.
Implementation Method 1
a vesicle is a nano-sized substance of about 20 nm to about 200 nm produced and released by cells, and can move freely between cells. In addition, such a vesicle contains membrane lipids, membrane proteins, DNA or RNA, etc., and these genetic materials are known to act as a complex to transfer cells and toxic factors between cells and play a role in regulating inflammation and immune responses.
Implementation Method 2
These strains and their derived products demonstrate significant anti-inflammatory and antibacterial effects, including reducing nitric oxide production, inhibiting inflammatory cytokines, and inhibiting bacterial growth
Implementation Method 3
These strains and their derived products demonstrate significant anti-inflammatory and antibacterial effects, including reducing nitric oxide production
Data Source
AI summary
The present disclosure relates to a novel microorganism, a lysate thereof, a culture solution thereof, an extract of the culture solution, a vesicle derived from the novel microorganism, and anti-inflammatory and/or antibacterial use of the foregoing. The novel strain and the vesicle derived therefrom according to an embodiment may be useful for the prevention, amelioration, or treatment of inflammation-related conditions or bacterial infections.